No Picture
News

ValGenesis VLMS Selected to Digitize the Validation Process of a Leading Italian Pharmaceutical Company

SAN FRANCISCO: SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ — ValGenesis, Inc., a market leader in enterprise Validation Lifecycle Management Systems (VLMS), today announced that a leading Italian pharmaceutical company selected ValGenesis VLMS – the ind… […]

No Picture
News

Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,… […]

No Picture
News

Deerfield and Stanford University Create the Porter Alliance for Innovative Medicines

SAN FRANCISCO & NEW YORK–(BUSINESS WIRE)–Stanford University and Deerfield Management, a healthcare investment firm, have collaborated to create Porter Alliance for Innovative Medicines to accelerate translational research into clinical therapeut… […]

No Picture
News

A $8 Billion Global Opportunity for Chloroform by 2026 – New Research from StrategyR

SAN FRANCISCO: SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Chloroform – Global Market Trajectory & Ana… […]

No Picture
News

Single-use Bioreactors Market Size Worth $7.76 Billion By 2028: Grand View Research, Inc.

SAN FRANCISCO: SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ — The global single-use bioreactors market size is expected to reach USD 7.76 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 17.0% … […]

No Picture
News

Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab

BURLINGAME, Calif.–(BUSINESS WIRE)—- $HGEN–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced a peer-reviewed… […]